3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
8
Breast Neoplasms
8
Prostatic Neoplasms
5
Small Cell Lung Carcinoma
4
Stomach Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Glioma
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Metastatic Castration-Resistant Prostate Cancer
1
Meningioma
1
Interventions
Abiraterone Acetate
2
onapristone
1
olaparib
1
gedatolisib
1
darolutamide
1
abiraterone
1
Radiotherapy
1
Pluvicto
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
EPI-506
1
Brachytherapy
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Diseases
×
olaparib
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled